Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01186861 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
A Phase 2 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 205
- Enrollment target
NCT01186861 is a Phase 2 study that has completed, run by Astellas Pharma. The registered enrollment target is 205 participants.
The verdict
NCT01186861, a Phase 2 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 205 participants
- Enrollment target
Study Summary
A multicenter, randomized, double-blind, placebo-controlled, phase 2 study with a 1:1 randomization scheme.
Interventions
- DRUG placebo
- DRUG erlotinib
- DRUG OSI-906
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2011-03-04 |
| Est. Completion | 2015-03-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01186861
The ClinicalTrials.gov registry entry for NCT01186861 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01186861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01186861 about?
NCT01186861 is a clinical study titled "Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy". A multicenter, randomized, double-blind, placebo-controlled, phase 2 study with a 1:1 randomization scheme.
What is the current status of trial NCT01186861?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 205 participants. The study started on 2011-03-04. Estimated completion is 2015-03-11.
What interventions are being tested in trial NCT01186861?
The interventions under investigation include: placebo (DRUG), erlotinib (DRUG), OSI-906 (DRUG).
Who is sponsoring clinical trial NCT01186861?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.